Idiopathic cranio-facial and cranio-cervical dystonia has previously been described as blepharospasm-oromandibular dystonia syndrome and referred to by the eponym Meige syndrome\[[@b1-jmd-7-2-92],[@b2-jmd-7-2-92]\]. It is characterized by the presence of bilateral dystonic spasms of the facial muscles, but in many cases, the involvement of other cranial muscles or other muscle groups of the neck or limbs can be present\[[@b1-jmd-7-2-92],[@b2-jmd-7-2-92]\].

The underlying cause of Meige syndrome is unknown, but most investigators believe this disease to be a variant of idiopathic torsion dystonia\[[@b3-jmd-7-2-92]\]. Meige syndrome typically begins in the fifth or sixth decade of life and is more common in females, at a 3:1 ratio\[[@b4-jmd-7-2-92],[@b5-jmd-7-2-92]\]. Medical treatment has remained limited due to frequent partial responses and adverse side effects. Botulinum toxin has been shown to be effective in treating Meige syndrome; however, some patients may experience diminished responses over time, and some may develop antibodies that make them resistant to continued therapy\[[@b6-jmd-7-2-92],[@b7-jmd-7-2-92]\].

Surgical neuromodulation using stereotactic techniques has been employed for several years, with mixed results. Both the thalamus and the globus pallidus interna (GPi) have been targeted. Renewed interest in the GPi related to medically refractory forms of generalized dystonia, as reported by Tronnier and Fogel\[[@b8-jmd-7-2-92]\], has sparked interest in targeting the GPi in patients suffering from Meige syndrome. Since Vercueil and coworkers first reported their results of bilateral GPi deep brain stimulation (DBS) in a patient with Meige syndrome, several studies have shown that segmental dystonia responds to GPi DBS\[[@b9-jmd-7-2-92]\]. However, the beneficial effects of GPi-DBS in patients with Meige syndrome remain to be established because the data is based on a small series of patients with short-term follow-up. We report another experience of using DBS in a case of Meige syndrome.

CASE REPORT
===========

This case report was approved by the ethics committee of Seoul St. Mary's Hospital, and the patient gave consent for video recording and academic use.

The patient, a 47-year-old woman, had suffered from insidious onset of blepharospasm, oromandibular dystonia, and spasmodic dysphonia for 2 years before visiting our neurology outpatient clinic. The patient complained of decreased social activity during the course of her disease due to hyperkinesia of facial muscles and functional blindness secondary to blepharospasm. The patient was never exposed to neuroleptics, nor did she have a family history of dystonia or any perioral trauma.

Upon examination, the patient demonstrated severe blepharospasm and oromandibular dystonia, which became aggravated when the patient attempted to open her eyes or tried to speak (Video 1 in the online-only Data Supplement). The results of neuropsychological testing for memory and frontal lobe functions were within normal limits. Evaluations were normal, including magnetic resonance imaging of the brain, serum chemistries, a complete blood count, serum ceruloplasmin, serum and urine copper levels, thyroid function tests, and genetic testing for the DYT1 mutation in the torsion A gene. The dental examination was also normal.

The patient had been treated with 50 mg quetiapine, 8 mg trihexiphenidyl, and 40 mg baclofen, but these drugs were not effective, and side effects of somnolence were observed. Considering both the treatment-resistant symptoms and the severe disabilities, we decided to perform bilateral GPi DBS to control her dystonic symptoms.

The initial stereotactic coordinates determined by MRI-stereotactic planning were established to target the posteroventral lateral GPi. Intraoperatively, neuronal recordings were obtained using multichannel microelectrode recordings. Postoperative CT and MRI were used to verify electrode position within the GPi and to exclude asymptomatic cerebral hemorrhage ([Figure 1](#f1-jmd-7-2-92){ref-type="fig"}). Postoperative programming of the DBS was performed 1 day after the staged implantation of the pulse generator. No delayed complications of the hardware occurred.

At 2 months after the surgery, all major clinical symptoms indicated significant improvement in blepharospasm and in oromandibular and orofacial dystonia (Video 2 in the online-only Data Supplement). Speech difficulties caused by spasmodic dysphonia and/or oromandibular dystonia also responded well to pallidal stimulation. No clinically relevant bradykinesia or other abnormal movement was observed in our patient, nor were depressive mood or emotional instability. The patient was satisfied with the symptom improvement. The parameters of GPi DBS were as follows: a pulse width of 60 μsec, frequency of 130 Hz, and stimulation amplitude of 2.1 V on the right side, and a width of 90 μsec, frequency of 130 Hz, and amplitude of 1.9 V on the left side.

DISCUSSION
==========

The exact mechanism of the observed effect of pallidal stimulation on dystonia remains unclear, but it is possible that DBS improves dystonic symptoms by changing the plasticity in the cortical-basal ganglia circuit\[[@b10-jmd-7-2-92],[@b11-jmd-7-2-92]\]. Thus, symptoms do not return immediately after the discontinuation of therapy, and continuous stimulation may not be needed in some of these patients\[[@b11-jmd-7-2-92]\].

The most effective target area within the GPi for controlling this symptom by DBS remains under debate. Moreover, which phenotypes among the symptoms constituting Meige syndrome will respond best to DBS also remain unknown. All of these uncertainties make the publication of all previous case series and our case report important for understanding the efficacy of GPi-DBS in Meige syndrome.

Blomstedt et al.\[[@b9-jmd-7-2-92]\] hypothesized that in patients with Meige syndrome and segmental dystonia, the GPi-DBS response may be better than in patients with purely cranio-facial dystonia. Houser and Waltz\[[@b3-jmd-7-2-92]\], in contrast, hypothesized that improvement could be predicted simply by the presence of isolated cranio-facial dystonia. Recently, the important observation was made that although disease duration can be a good predictor of the outcome of pallidal stimulation in patients with primary dystonias, no particular predictive value should be assigned to age at onset, age at surgery, severity of disease, DYT1 status or the presence of phasic or tonic involuntary movements\[[@b12-jmd-7-2-92]\].

Numerous GPi-DBS studies have reported various adverse effects on the limbic system. Two recent reports indicated bradykinesia as a therapy-related adverse effect of pallidal neurostimulation in Meige syndrome at high voltage\[[@b13-jmd-7-2-92],[@b14-jmd-7-2-92]\]. Cases of mania, depression, suicide and suicide ideations were observed in connection to pallidal stimulation.\[[@b15-jmd-7-2-92]\] Foncke et al. \[[@b16-jmd-7-2-92]\], who reported two suicides in 16 GPi-DBS treated dystonic patients, stated that these findings illustrate that there is a prominent risk of suicide after DBS of the GPi in medication-refractory dystonia.

In summary, this case report, in combination with other previous reports, suggests that bilateral GPi DBS may be an effective treatment for medically refractory Meige syndrome, without significant adverse effects.
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The online-only Data Supplement is available with this article at <http://dx.doi.org/10.14802/jmd.14013>.
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